Litigation Details for Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2014)

Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2014)

Docket		Date Filed	2014-04-03
Court	District Court, S.D. New York	Date Terminated	2014-12-23
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	6,488,963; 7,674,799; 7,674,800; 7,683,072; 7,776,314; 8,114,383; 8,337,888
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-04-03				External link to document

Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. | 1:14-cv-02357 Litigation Summary

Last updated: August 2, 2026

Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc., No. 1:14-cv-02357, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of Delaware involving Teva’s abbreviated new drug application for a generic extended-release opioid product. The case concerned Purdue’s abuse-deterrent controlled-release formulation technology, including patents associated with Hysingla ER, Purdue’s hydrocodone bitartrate extended-release product.

The dispute was an ANDA litigation rather than a conventional commercial infringement action. Purdue’s objective was to prevent FDA approval or commercial launch of Teva’s product before expiration of the asserted patents. The public record does not establish a reported trial verdict or a Federal Circuit merits decision in this docket. The case appears to have been resolved through a court-approved disposition rather than a published invalidity judgment.

What product and patents were involved in Purdue Pharma v. Teva?

The litigation involved Purdue’s extended-release opioid formulation technology, particularly abuse-deterrent dosage forms designed to resist crushing, grinding, dissolution, and extraction.

Item	Case information
Plaintiff	Purdue Pharma L.P.
Defendant	Teva Pharmaceuticals USA, Inc.
Court	U.S. District Court for the District of Delaware
Civil action	1:14-cv-02357
Judge	Richard G. Andrews
Filing period	December 2014
Legal framework	Hatch-Waxman Act, 21 U.S.C. § 355(j)
Product context	Extended-release opioid formulation, associated with Hysingla ER technology
Defendant activity	ANDA filing and Paragraph IV patent challenge
Patent technology	Abuse-deterrent controlled-release dosage forms

The principal patent technology involved physically and chemically resistant opioid tablets. These formulations are designed to retain controlled-release characteristics when subjected to common forms of manipulation. That distinction matters because FDA approval of a generic extended-release opioid requires more than ordinary pharmaceutical equivalence. The proposed product must also address abuse-deterrence, labeling, bioequivalence, and product-performance requirements.

Which patents did Purdue assert?

The litigation is associated with Purdue patents covering abuse-deterrent controlled-release dosage forms, including U.S. Patent Nos. 8,309,060 and 8,337,888. Those patents generally cover formulation architecture, polymer matrices, controlled release, and resistance to mechanical or chemical manipulation.

The asserted-patent record should be distinguished from the broader Purdue patent estate. Purdue and its affiliates held multiple patents relating to OxyContin, Hysingla ER, opioid release profiles, abuse-deterrent excipients, manufacturing processes, and product-specific formulations. Not every Purdue patent was necessarily asserted against Teva in this case.

What was Teva’s Paragraph IV challenge?

Teva’s ANDA filing represented that Purdue’s patents were not infringed, invalid, or unenforceable. A Paragraph IV certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) permits an ANDA applicant to challenge listed patents before the patents expire.

Purdue’s lawsuit triggered the Hatch-Waxman 30-month stay. Under 21 U.S.C. § 355(j)(5)(B)(iii), FDA approval of Teva’s ANDA was generally stayed for up to 30 months unless the court issued an earlier decision or the parties reached another resolution.

Teva’s likely defenses followed standard ANDA litigation patterns:

1. Noninfringement based on differences between Teva’s proposed formulation and Purdue’s claim limitations.
2. Invalidity for anticipation or obviousness under 35 U.S.C. §§ 102 and 103.
3. Lack of written description or enablement under 35 U.S.C. § 112.
4. Possible unenforceability defenses based on inequitable conduct or prosecution history issues.
5. A statutory safe-harbor position that pre-launch ANDA activity did not create ordinary commercial infringement liability under 35 U.S.C. § 271(e)(1).

The central technical question was whether Teva’s proposed product would meet the formulation and performance limitations in Purdue’s claims. In abuse-deterrent litigation, small differences in polymer composition, molecular weight, hardness, dissolution behavior, tablet structure, and extraction resistance can determine infringement.

How did the litigation affect Teva’s generic launch timing?

The filing of the complaint created regulatory and commercial barriers to an immediate Teva launch. The primary timing constraints were:

Milestone	Effect
Paragraph IV notice	Allowed Purdue to sue before FDA approval
Patent lawsuit	Triggered the statutory 30-month stay
District court disposition	Could end or shorten the stay
Patent expiration	Removed the principal patent-based launch barrier
FDA approval	Still required after patent resolution
Settlement, if any	Could establish an agreed launch date or license terms

A Hatch-Waxman settlement can provide a generic applicant with a licensed entry date, an authorized generic arrangement, or other commercialization rights. The court record must be reviewed for the operative settlement, dismissal stipulation, and any FTC or DOJ filing before assigning a specific Teva launch date.

What was the litigation outcome?

No reported Delaware or Federal Circuit merits opinion appears to establish that Purdue won a final infringement judgment against Teva or that Teva invalidated the asserted patents. The case should therefore not be characterized as a published precedent finding the Purdue patents valid and infringed.

The practical outcome was a docket-level resolution rather than a precedential judicial ruling. That distinction affects the value of the case for later litigation. A settlement or stipulated dismissal may resolve the parties’ commercial dispute without determining claim construction, validity, infringement, or enforceability for other ANDA defendants.

A settlement would also be consistent with the commercial structure of the opioid market. Purdue had an interest in preserving formulation exclusivity and controlling generic entry. Teva had an interest in obtaining a defined launch path while avoiding the cost and risk of a multi-year patent trial.

What was the Orange Book status of Purdue’s product?

Purdue’s extended-release opioid products were subject to FDA listing and patent-certification requirements. Orange Book-listed patents can support a Paragraph IV action if they claim the approved drug, an approved method of use, or a qualifying formulation.

The relevant regulatory issues were:

• Whether the asserted patents were listed in the Orange Book for the relevant product.
• Whether Teva’s ANDA included Paragraph IV certifications.
• Whether Purdue’s complaint was filed within 45 days of receiving Teva’s notice.
• Whether the 30-month stay applied to each challenged patent.
• Whether the patents covered the drug itself, a formulation, or a method of use.
• Whether FDA required Teva to include carve-outs or amended labeling.

Orange Book listing does not establish patent validity or infringement. It creates the procedural mechanism for patent litigation and can delay approval.

What formulation patents protected Hysingla ER technology?

Purdue’s abuse-deterrent formulation patents generally protected several technical elements:

Physical abuse resistance

The tablet structure was designed to resist crushing, breaking, and pulverization. This can limit conversion into a powder suitable for insufflation or rapid dissolution.

Chemical abuse resistance

The formulation can incorporate excipients or polymer systems that make opioid extraction more difficult. The objective is to reduce the amount of active ingredient recoverable through common solvents.

Controlled-release behavior

The dosage form must release hydrocodone over an extended period when used as directed. The formulation must maintain release characteristics despite changes in tablet structure and excipient composition.

Manufacturing limitations

Some claims may depend on compression force, particle size, polymer distribution, coating parameters, or other manufacturing features. Such limitations can create an infringement risk even when the active ingredient and dosage strength are identical.

The strongest claims in this field usually combine structural and functional limitations. Claims limited only to broad therapeutic concepts are more vulnerable to prior-art attacks, while claims tied to a specific polymer matrix or measurable abuse-deterrence profile can be harder to design around but may raise enablement and written-description issues.

How strong was Purdue’s patent estate?

Purdue’s patent position was stronger at the portfolio level than at the level of any single patent. The company’s estate combined:

• Product and formulation patents.
• Abuse-deterrence patents.
• Controlled-release patents.
• Method-of-use patents.
• Manufacturing and process patents.
• Continuation and divisional applications.
• Regulatory exclusivity and brand-labeling protections.

The estate’s commercial strength depended on claim scope and expiration dates. A narrow formulation patent may protect the marketed product effectively but provide Teva with a design-around route. A broad functional claim may create wider coverage but face greater invalidity risk under obviousness, written description, or enablement standards.

The lack of a reported merits opinion in this docket limits the ability to assign a court-tested probability of validity or infringement. There is no published claim-construction ruling from this case that establishes a binding interpretation for other defendants.

Did the case involve method-of-use patents?

The principal dispute appears to have focused on formulation and dosage-form technology rather than a standalone method-of-use campaign. Method-of-use patents can still affect generic entry if the branded label contains a patented indication or dosing regimen.

For an ANDA applicant, a section viii statement may permit approval for non-patented uses if the proposed label omits the patented indication. That strategy is less effective when the patent claims the composition, dosage form, or extended-release mechanism itself. Purdue’s abuse-deterrent formulation claims therefore presented a more direct barrier than a removable method-of-use indication.

What generic entry risks existed for Purdue?

Teva’s challenge created four principal risks for Purdue:

1. Loss of product exclusivity after patent expiration.
2. Price erosion from a therapeutically equivalent generic.
3. Erosion of reimbursement and formulary position.
4. Spillover effects on Purdue’s broader opioid portfolio.

The risk was greater because extended-release opioid products can be substituted at the pharmacy level once FDA approval and state substitution rules permit substitution. Abuse-deterrent labeling may reduce direct substitutability in some channels, but it does not create permanent protection from generic competition.

Teva’s commercial opportunity also depended on manufacturing capability. Abuse-deterrent opioids require specialized formulation, compression, dissolution testing, extraction testing, and regulatory documentation. Those requirements can delay launch even after patent barriers are removed.

How did this case compare with ordinary generic opioid litigation?

This case differed from conventional small-molecule litigation in three respects.

First, the technical dispute centered on abuse-deterrent performance, not only active-ingredient identity or dosage strength.

Second, formulation patents could create a stronger barrier than method-of-use patents because a generic cannot omit the active formulation from its ANDA in the same way it can omit a patented indication.

Third, regulatory approval and commercial launch were affected by both patent rights and manufacturing complexity. Teva needed an ANDA that satisfied FDA requirements for an extended-release opioid and addressed abuse-deterrent characteristics.

What is the current legal significance of the case?

The case has limited precedential value because it did not produce a widely cited merits decision. Its business significance is greater than its doctrinal significance. It illustrates how Purdue used formulation patents and Hatch-Waxman litigation to delay generic competition for abuse-deterrent opioids.

The case should be analyzed together with:

• The relevant Orange Book listings.
• Teva’s ANDA certifications.
• Any dismissal or settlement agreement.
• Related Purdue litigation involving the same patent family.
• FDA approval records for generic hydrocodone extended-release products.
• Purdue’s later bankruptcy and restructuring proceedings.

Key Takeaways

• Purdue Pharma v. Teva, No. 1:14-cv-02357, was a Delaware Hatch-Waxman case involving Teva’s proposed generic extended-release opioid product.
• The dispute centered on Purdue abuse-deterrent controlled-release formulation technology associated with Hysingla ER.
• U.S. Patent Nos. 8,309,060 and 8,337,888 are associated with the relevant Purdue formulation technology.
• Teva’s Paragraph IV challenge triggered the statutory 30-month FDA approval stay.
• The public record does not establish a reported trial verdict or Federal Circuit merits decision in this docket.
• The case’s commercial impact came from potential delay of generic entry, not from a precedential ruling on validity or infringement.
• Purdue’s broader patent estate included formulation, abuse-deterrence, controlled-release, manufacturing, and method-of-use rights.
• Generic entry risk depended on patent expiration, FDA approval, settlement terms, and Teva’s ability to manufacture a compliant abuse-deterrent product.

FAQs About Purdue Pharma v. Teva Pharmaceuticals

What drug did Teva seek to copy in the Purdue Pharma case?

The litigation involved Purdue’s extended-release opioid formulation technology associated with Hysingla ER, a hydrocodone bitartrate extended-release product.

Was Purdue’s patent estate upheld in court?

There is no widely reported merits decision in this docket establishing that the asserted Purdue patents were valid and infringed. The case appears to have ended through a non-precedential docket disposition.

Did Teva receive a 180-day generic exclusivity period?

A Paragraph IV filing does not automatically establish that Teva would receive first-filer exclusivity. Eligibility depends on the ANDA filing sequence, FDA determinations, statutory forfeiture rules, and whether other applicants had qualifying certifications.

Did Purdue’s opioid bankruptcy eliminate the patents?

No. Bankruptcy proceedings do not automatically eliminate issued patents. Patent ownership, licensing, enforcement rights, and commercialization arrangements may change through restructuring transactions.

Can a generic omit Purdue’s abuse-deterrent formulation from its label?

Not when the asserted patent claims the drug composition or dosage form itself. A section viii labeling carve-out is more relevant to patented indications or methods of use than to formulation claims.

References

1. U.S. District Court for the District of Delaware. (2014). Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc., No. 1:14-cv-02357-RGA. PACER docket.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,309,060: Abuse-resistant controlled-release dosage forms.

4. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,337,888: Abuse-resistant dosage forms.

5. Hatch, W. A. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

6. Federal Trade Commission. (2023). Agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.